[{"id":"73f525e9-88d1-49d4-a2a6-9faf82456aae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262491","created_at":"2022-11-08T18:28:24.724Z","updated_at":"2025-02-25T15:35:30.552Z","phase":"Phase 1","brief_title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor","source_id_and_acronym":"NCT05262491","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-18"},{"id":"3ab273df-ad84-463e-809d-9cbd385707ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990803","created_at":"2023-08-14T14:10:30.823Z","updated_at":"2025-02-25T15:36:27.652Z","phase":"Phase 2","brief_title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","source_id_and_acronym":"NCT05990803","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/06/2023","start_date":" 11/06/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-24"},{"id":"20c1edcd-7b1a-4a0e-a322-cf7af957ea0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008054","created_at":"2023-08-23T15:11:10.298Z","updated_at":"2025-02-25T15:36:29.034Z","phase":"Phase 2","brief_title":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","source_id_and_acronym":"NCT06008054","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 376","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-09-25"},{"id":"6478b2e2-568c-410e-9877-3d989cfbdd71","acronym":"","url":"https://clinicaltrials.gov/study/NCT05880706","created_at":"2023-05-30T14:05:24.607Z","updated_at":"2025-02-25T15:36:16.707Z","phase":"Phase 2","brief_title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05880706","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-08-07"},{"id":"6bf2b896-e018-4a72-8241-0b41b1b66f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06118333","created_at":"2023-11-07T20:13:25.871Z","updated_at":"2025-02-25T15:36:37.862Z","phase":"Phase 3","brief_title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT06118333","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 368","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-18"},{"id":"8ffc43aa-6147-4c99-a983-e627e958440f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06042894","created_at":"2023-09-21T16:11:01.150Z","updated_at":"2025-02-25T15:36:32.414Z","phase":"Phase 2","brief_title":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT06042894","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-18"}]